^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CARv3-TEAM-E T cells
i
Other names: CARv3-TEAM-E T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Massachusetts General Hospital
Drug class:
EGFRvIII-targeted CAR-T immunotherapy
Related drugs:
8ms
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. (PubMed, N Engl J Med)
Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR wild-type
|
CARv3-TEAM-E T cells
over1year
CARv3-TEAM-E T Cells in Glioblastoma (clinicaltrials.gov)
P1, N=21, Recruiting, Marcela V. Maus, M.D.,Ph.D. | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jun 2025
Enrollment open • Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
EGFR amplification • EGFRvIII mutation
|
CARv3-TEAM-E T cells
almost2years
CARv3-TEAM-E T Cells in Glioblastoma (clinicaltrials.gov)
P1, N=21, Not yet recruiting, Marcela V. Maus, M.D.,Ph.D.
New P1 trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
EGFR amplification • EGFRvIII mutation
|
CARv3-TEAM-E T cells
Share via
